Abstract
Objective: To examine the incremental cost effectiveness of the five first line pharmacological smoking cessation therapies in the Seychelles and other developing countries.
Design: A Markov chain cohort simulation.
Subjects: Two simulated cohorts of smokers: (1) a reference cohort given physician counselling only; (2) a treatment cohort given counselling plus cessation therapy.
Intervention: Addition of each of the five pharmacological cessation therapies to physician provided smoking cessation counselling.
Main outcome measures: Cost per life-year saved (LYS) associated with the five pharmacotherapies. Effectiveness expressed as odds ratios for quitting associated with pharmacotherapies. Costs based on the additional physician time required and retail prices of the medications.
Results: Based on prices for currently available generic medications on the global market, the incremental cost per LYS for a 45 year old in the Seychelles was US$599 for gum and $227 for bupropion. Assuming US treatment prices as a conservative estimate, the incremental cost per LYS was significantly higher, though still favourable in comparison to other common medical interventions: $3712 for nicotine gum, $1982 for nicotine patch, $4597 for nicotine spray, $4291 for nicotine inhaler, and $1324 for bupropion. Cost per LYS increased significantly upon application of higher discount rates, which may be used to reflect relatively high opportunity costs for health expenditures in developing countries with highly constrained resources and high overall mortality.
Conclusion: Pharmacological cessation therapy can be highly cost effective as compared to other common medical interventions in low mortality, middle income countries, particularly if medications can be procured at low prices.
Full Text
The Full Text of this article is available as a PDF (73.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bovet P., Shamlaye C., Kitua A., Riesen W. F., Paccaud F., Darioli R. High prevalence of cardiovascular risk factors in the Seychelles (Indian Ocean). Arterioscler Thromb. 1991 Nov-Dec;11(6):1730–1736. doi: 10.1161/01.atv.11.6.1730. [DOI] [PubMed] [Google Scholar]
- Cornuz Jacques, Pinget Christophe, Gilbert Allison, Paccaud Fred. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol. 2003 May 21;59(3):201–206. doi: 10.1007/s00228-003-0610-6. [DOI] [PubMed] [Google Scholar]
- Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994 Oct 8;309(6959):901–911. doi: 10.1136/bmj.309.6959.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ernster V., Kaufman N., Nichter M., Samet J., Yoon S. Y. Women and tobacco: moving from policy to action. Bull World Health Organ. 2000;78(7):891–901. [PMC free article] [PubMed] [Google Scholar]
- Fiscella K., Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996 Apr 24;275(16):1247–1251. [PubMed] [Google Scholar]
- Gilpin E. A., Pierce J. P., Farkas A. J. Duration of smoking abstinence and success in quitting. J Natl Cancer Inst. 1997 Apr 16;89(8):572–576. doi: 10.1093/jnci/89.8.572. [DOI] [PubMed] [Google Scholar]
- Jackson G., Bobak A., Chorlton I., Fowler G., Hall R., Khimji H., Matthews H., Stapleton J., Steele C., Stillman P. Smoking cessation: a consensus statement with special reference to primary care. Int J Clin Pract. 2001 Jul-Aug;55(6):385–392. [PubMed] [Google Scholar]
- Kupersmith J., Holmes-Rovner M., Hogan A., Rovner D., Gardiner J. Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. Prog Cardiovasc Dis. 1995 Jan-Feb;37(4):243–271. doi: 10.1016/s0033-0620(05)80009-x. [DOI] [PubMed] [Google Scholar]
- Oster G., Huse D. M., Delea T. E., Colditz G. A. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA. 1986 Sep 12;256(10):1315–1318. [PubMed] [Google Scholar]
- Perret F., Bovet P., Shamlaye C., Paccaud F., Kappenberger L. High prevalence of peripheral atherosclerosis in a rapidly developing country. Atherosclerosis. 2000 Nov;153(1):9–21. doi: 10.1016/s0021-9150(00)00376-2. [DOI] [PubMed] [Google Scholar]
- Peto R., Darby S., Deo H., Silcocks P., Whitley E., Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000 Aug 5;321(7257):323–329. doi: 10.1136/bmj.321.7257.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Prochaska J. O., Goldstein M. G. Process of smoking cessation. Implications for clinicians. Clin Chest Med. 1991 Dec;12(4):727–735. [PubMed] [Google Scholar]
- Rogers R. G., Powell-Griner E. Life expectancies of cigarette smokers and nonsmokers in the United States. Soc Sci Med. 1991;32(10):1151–1159. doi: 10.1016/0277-9536(91)90092-q. [DOI] [PubMed] [Google Scholar]
- Song Fujian, Raftery James, Aveyard Paul, Hyde Chris, Barton Pelham, Woolacott Nerys. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S26–S37. doi: 10.1177/027298902237708. [DOI] [PubMed] [Google Scholar]
- Wasley M. A., McNagny S. E., Phillips V. L., Ahluwalia J. S. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med. 1997 Mar-Apr;26(2):264–270. doi: 10.1006/pmed.1996.0127. [DOI] [PubMed] [Google Scholar]
- Woolacott N. F., Jones L., Forbes C. A., Mather L. C., Sowden A. J., Song F. J., Raftery J. P., Aveyard P. N., Hyde C. J., Barton P. M. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):1–245. doi: 10.3310/hta6160. [DOI] [PubMed] [Google Scholar]